Life Neuroscience
NeuroLife
Sun, Nov 15, 2026
[Archive]
Volume 2, Issue 1 (1-2024)
Neuroscience Updates 2024, 2(1): 1-24 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ajayi E I O, Babatunde I O, Oladele J O. Carotenoids and Their Formulation Supplements in Alzheimer’s Disease. Neuroscience Updates 2024; 2 (1) :1-24
URL: http://neuroupdates.de/article-1-107-en.html
URL: http://neuroupdates.de/article-1-107-en.html
1- Department of Biochemistry, Faculty of Basic and Applied Sciences, College of Science, Engineering and Technology, Osun State University,P. M. B. 4494, OkeBaale, Osogbo, Nigeria
2- Department of Biochemistry, Faculty of Basic and Applied Sciences, College of Science, Engineering and Technology, Osun State University,P. M. B. 4494, OkeBaale, Osun State University, Osogbo, Nigeria
3- Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A & M University, College Station, Texas, USA
2- Department of Biochemistry, Faculty of Basic and Applied Sciences, College of Science, Engineering and Technology, Osun State University,P. M. B. 4494, OkeBaale, Osun State University, Osogbo, Nigeria
3- Department of Veterinary Physiology and Pharmacology, College of Veterinary Medicine and Biomedical Sciences, Texas A & M University, College Station, Texas, USA
Abstract: (10886 Views)
Alzheimer’s disease is a type of neurodegenerative disease that is mistakenly confused with aging and is oftentimes misdiagnosed. One of its main characteristics is the loss of nerve connections and functioning neurons in the cerebral cortex and some subcortical areas. The sheer number of people affected by neurodegenerative diseases globally is startling, but this is at the top of the list. Called memory loss disorder, it starts slowly and gets worse over the years. This seemingly incurable and severely crippling neurodegenerative dementing disorder affects the hippocampus. Changes in this region's physio-anatomical function lead to inability to form new memory traces or entire memory loss that is linked to brain impairment. The pathophysiology of Alzheimer's disease has been linked to protein misfolding, where folded amyloid beta proteins in neurons and brain tissues are replaced by larger pathogenic proteins known to aggregate. Clinically recognized early-stage symptoms include language issues, apraxia, challenges with perceiving, writing, dressing, other motor skills, and difficulty with movement coordination. Diagnostic criteria have identified middle-stage symptoms as speech difficulties in the patient, most notably paraphasia, inability to identify family members, unguarded aggression, lack of civility when urinating, and other neuropsychiatric-behavioral changes. Severe symptoms include total dependence on the caregiver and total loss of speech. Even though there are no proven treatments, new research highlights the possible roles that certain dietary components most especially carotenoids may play in both management and prevention. With recent advances in biotechnology, genome editing, and AI-driven precise and personalized medicine, there is hope that the absorption, distribution, metabolism, and excretion of carotenoid supplements can be optimized for increased bioavailability along the gut-brain axis and efficient blood-brain barrier crossing. The emerging possibilities present a strong opportunity to enhance the therapeutic impact of carotenoids on Alzheimer’s disease.
Type of Study: Review Article |
Subject:
Neurodegenerative Disease
Received: 2023/12/20 | Accepted: 2024/02/15 | Published: 2024/04/30
Received: 2023/12/20 | Accepted: 2024/02/15 | Published: 2024/04/30
References
1. Hamilton RL. Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using alpha-synuclein immunohistochemistry. Brain Pathol. 2000;10(3):378-384. [DOI:10.1111/j.1750-3639.2000.tb00269.x] [PMID] [PMCID]
2. Oladele JO, Oladiji AT, Oladele OT, Oyeleke OM. Reactive oxygen species in neurodegenerative diseases: Implications in pathogenesis and treatment strategies. IntechOpen. 2021.
3. Wenk GL. Neuropathologic changes in Alzheimer's disease. J Clin Psychiatry. 2003;64(Suppl 9):7-10.
4. Oladele JO, Oyeleke OM, Oladele OT, Olaniyan MD. Neuroprotective mechanism of Vernonia amygdalina in a rat model of neurodegenerative diseases. Toxicol Rep. 2020;7:1223-1232. [DOI:10.1016/j.toxrep.2020.09.005] [PMID] [PMCID]
5. Berchtold NC, Cotman CW. Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s. Neurobiol Aging. 1998;19(3):173-189. [DOI:10.1016/S0197-4580(98)00052-9] [PMID]
6. Simon RP, Greenberg DA, Aminoff MJ. Clinical neurology. 10th ed. New York: McGraw Hill; 2018. p. 111. ISBN 978-1-259-86173-4.
7. Oladele JO, Oladele OT, Adewole TS, Oyeleke OM, Oladiji AT. Phytochemicals and natural products: Efficacy in the management/treatment of neurodegenerative diseases. In: Handbook of Research on Advanced Phytochemicals and Plant-Based Drug Discovery. Chapter 10. 2022. [DOI:10.4018/978-1-6684-5129-8.ch010]
8. Taler V, Phillips NA. Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review. J Clin Exp Neuropsychol. 2008;30(5):501-556. [DOI:10.1080/13803390701550128] [PMID]
9. Tackenberg C, Kulic L, Nitsch RM. Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system. PLOS ONE. 2020;15(9). [DOI:10.1371/journal.pone.0239584] [PMID] [PMCID]
10. Sun W, Samimi H, Gamez M, Zare H, Frost B. Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies. Nat Neurosci. 2018;21(8):1038-1048. [DOI:10.1038/s41593-018-0194-1] [PMID]
11. Sinyor B, Mineo J, Ochner C. Alzheimer's disease inflammation, and the role of antioxidants. J Alzheimers Dis Rep. 2018;4(1):175-183. [DOI:10.3233/ADR-200171] [PMID] [PMCID]
12. Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019;103(2):263-293. [DOI:10.1016/j.mcna.2018.10.009] [PMID]
13. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc Natl Acad Sci USA. 2006;103(15):5644-5651. [DOI:10.1073/pnas.0600549103] [PMID]
14. Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000 Research. 2018;7:1161. [DOI:10.12688/f1000research.14506.1] [PMID] [PMCID]
15. Chu CS, Tseng PT, Stubbs B, et al. Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis. Sci Rep. 2018;8(1):5804. [DOI:10.1038/s41598-018-24248-8] [PMID] [PMCID]
16. Yu JT, Xu W, Tan CC, et al. Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020;91(11):1201-1209. [DOI:10.1136/jnnp-2019-321913] [PMID] [PMCID]
17. Hira S, Saleem U, Anwar F, Sohail MF, Raza Z, Ahmad B. β-Carotene: A natural compound improves cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer's disease. Biomolecules. 2019;9(9):441. [DOI:10.3390/biom9090441] [PMID] [PMCID]
18. Abrego-Guandique DM, Bonet ML, Caroleo MC, Cannataro R, Tucci P, Ribot J, et al. The effect of beta-carotene on cognitive function: A systematic review. Brain Sci. 2023 Oct 17;13(10):1468. [DOI:10.3390/brainsci13101468] [PMID] [PMCID]
19. Rather MA, Khan A, Alshahrani S, Rashid H, Qadri M, Rashid S, et al. Inflammation and Alzheimer's Disease: Mechanisms and Therapeutic Implications by Natural Products. Mediators of Inflammation. 2021;2021:9982954. [DOI:10.1155/2021/9982954] [PMID] [PMCID]
20. Kaspers DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J. Harrison's Principles of internal medicine. New York: McGraw-Hill Companies; 2015. p. 24-45.
21. Kim YS, Joh TH. Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Exp Mol Med. 2006;38:333-47. [DOI:10.1038/emm.2006.40] [PMID]
22. Jellinger KA. Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med. 2010;14(3):457-48. [DOI:10.1111/j.1582-4934.2010.01010.x] [PMID] [PMCID]
23. Murphy MP, LeVine H. Alzheimer's disease and the amyloid-β peptide. J Alzheimer's Dis. 2010;19:311. [DOI:10.3233/JAD-2010-1221] [PMID] [PMCID]
24. Chi H, Chang H, Sang T. Neuronal Cell Death Mechanisms in Major Neurodegenerative Diseases. Int J Mol Sci. 2019;19:3082. [DOI:10.3390/ijms19103082] [PMID] [PMCID]
25. Martínez-Pinilla E, Ordóñez C, Del Valle E, Navarro A, Tolivia J. Regional and gender study of neuronal density in brain during aging and in Alzheimer's disease. Front Aging Neurosci. 2016;8:213. [DOI:10.3389/fnagi.2016.00213] [PMID] [PMCID]
26. Cunningham C, Wilcockson DC, Campion S, Lunnon K, Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. J Neurosci. 2005;25(40):9275-9284. [DOI:10.1523/JNEUROSCI.2614-05.2005] [PMID] [PMCID]
27. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol. 2010;11:155-61. [DOI:10.1038/ni.1836] [PMID] [PMCID]
28. Querfurth HW, LaFerla FM. Alzheimer's disease. N Engl J Med. 2010;362:329-44. [DOI:10.1056/NEJMra0909142] [PMID] [PMCID]
29. Bradshaw EM, Chibnik LB, Keenan BT, et al, and the Alzheimer Disease Neuroimaging Initiative. CD33 Alzheimer's disease locus: altered monocyte function and amyloid biology. Nat Neurosci. 2013;16:848-50. [DOI:10.1038/nn.3435] [PMID] [PMCID]
30. Medeiros R, LaFerla FM. Astrocytes: conductors of the Alzheimer disease neuroinflammatory symphony. Exp Neurol. 2013;239:133-38. [DOI:10.1016/j.expneurol.2012.10.007] [PMID]
31. Olabarria M, Noristani HN, Verkhratsky A, Rodríguez JJ. Concomitant astroglial atrophy and astrogliosis in a triple transgenic animal model of Alzheimer's disease. Glia. 2010;58:831-38. [DOI:10.1002/glia.20967] [PMID] [PMCID]
32. Heneka MT, Carson MJ, Khoury J, Landreth GE. Neuroinflammation in Alzheimer's disease. Lancet Neurol. 2015;14:388-405. [DOI:10.1016/S1474-4422(15)70016-5] [PMID]
33. Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT. Inflammation as a central mechanism in Alzheimer's disease. Alzheimers Dement (N Y). 2018;4:575-90. [DOI:10.1016/j.trci.2018.06.014] [PMID] [PMCID]
34. Cioffi F, Adam RH, Broersen K. Molecular mechanisms and genetics of oxidative stress in Alzheimer's disease. J Alzheimers Dis. 2019;72:981-1017. [DOI:10.3233/JAD-190863] [PMID] [PMCID]
35. Sies H, Jones DP. Reactive oxygen species (ROS) as pleiotropic physiological signalling agents. Nat Rev Mol Cell Biol. 2020;21:363-383. [DOI:10.1038/s41580-020-0230-3] [PMID]
36. Lobo V, Patil A, Phatak A, Chandra N. Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev. 2010;4(8):118-126. [DOI:10.4103/0973-7847.70902] [PMID] [PMCID]
37. Oladele JO, Oyeleke OM, Akindolie BO, Olowookere BD, Oladele OT. Vernonia amygdalina abates oxidative hepatic damage and inflammation associated with nitrobenzene in rat. Jordan J Biol Sci. 2021;14(3):463-469. [DOI:10.54319/jjbs/140311]
38. Oladele JO, Anyim JC, Oyeleke OM, Olowookere BD, Bamigboye MO, Oladele OO, Oladiji AT. Telfairia occidentalis mitigates dextran sodium sulphate-induced ulcerative colitis in rats via suppression of oxidative stress, lipid peroxidation and inflammation. J Food Biochem. 2021;45(9):e13873. [DOI:10.1111/jfbc.13873]
39. Oladele JO, Oyeleke OM, Olowookere BD, Babatope OD, Olaniyan MD, Akindolie BO, Oladele OT. Bitter leaf (Vernonia amygdalina) modulates nitrobenzene-induced renal damage in rats via suppression of oxido-inflammatory activities. Serb J Exp Clin Res. 2021;4:317-324. [DOI:10.2478/sjecr-2020-0040]
40. Oladele JO, Ajayi EIO, Oyeleke OM, Oladele OT, Olowookere BD, Adeniyi BM, Oyewole OI, Oladiji AT. A systematic review on COVID-19 pandemic with special emphasis on Curative potentials of medicinal plants. Heliyon. 2020;6:e05760. [DOI:10.1016/j.heliyon.2020.e04897] [PMID] [PMCID]
41. Cassidy L, Fernandez F, Johnson JB, Naiker M, Owoola AGD, Broszczak DA. Oxidative stress in Alzheimer's disease: A review on emergent natural polyphenolic therapeutics. Complement Ther Med. 2020;49:102294. [DOI:10.1016/j.ctim.2019.102294] [PMID]
42. Misrani A, Tabassum S, Yang L. Mitochondrial Dysfunction and Oxidative Stress in Alzheimer's Disease. Front Aging Neurosci. 2021;13:617588. [DOI:10.3389/fnagi.2021.617588] [PMID] [PMCID]
43. Hao C, Hui-Yun C, Tzu-Kang S. Neuronal cell death mechanisms in major neurodegenerative diseases. Int J Mol Sci. 2018;19:3082. [DOI:10.3390/ijms19103082] [PMID] [PMCID]
44. Fabiani C, Antollini SS. Alzheimer's disease as a membrane disorder: Spatial crosstalk among beta-amyloid peptides, nicotinic acetylcholine receptors and lipid rafts. Front Cell Neurosci. 2019;13:309. [DOI:10.3389/fncel.2019.00309] [PMID] [PMCID]
45. Gauba E, Chen H, Guo L, Du H. Cyclophilin D deficiency attenuates mitochondrial F1Fo ATP synthase dysfunction via OSCP in Alzheimer's disease. Neurobiol Dis. 2019;121:138-147. [DOI:10.1016/j.nbd.2018.09.020] [PMID] [PMCID]
46. Gella A, Durany N. Oxidative stress in Alzheimer disease. Cell Adhesion & Migration. 2009;3(1):88-93. [DOI:10.4161/cam.3.1.7402] [PMID] [PMCID]
47. Wang X, Wang W, Li L, Perry G, Lee HG, Zhu X. Oxidative stress and mitochondrial dysfunction in Alzheimer's disease. BiochimBiophys Acta. 2014;1842(8):1240-7. [DOI:10.1016/j.bbadis.2013.10.015] [PMID] [PMCID]
48. Cristóvão JS, Santos R, Gomes CM. Metals and neuronal metal binding proteins implicated in Alzheimer's disease. Oxid Med Cell Longev. 2016;2016. [DOI:10.1155/2016/9812178] [PMID] [PMCID]
49. Sun X-Y, et al. Synaptic released zinc promotes tau hyperphosphorylation by inhibition of protein phosphatase 2A (PP2A). J Biol Chem. 2012;287(14):11174-11182. [DOI:10.1074/jbc.M111.309070] [PMID] [PMCID]
50. Islam BU, Jabir NR, Tabrez S. The role of mitochondrial defects and oxidative stress in Alzheimer's disease. J Drug Targ. 2019;27(9):932-942. [DOI:10.1080/1061186X.2019.1584808] [PMID]
51. Du H, Guo L, Yan SS. Synaptic mitochondrial pathology in Alzheimer's disease. Antioxid Redox Signal. 2012;16:1467-1475. [DOI:10.1089/ars.2011.4277] [PMID] [PMCID]
52. Ferreira-Vieira TH, Guimaraes IM, Silva FR, Ribeir FM. Alzheimer's Disease: Targeting the Cholinergic System. CurrNeuropharmacol. 2016;14:101-115. [DOI:10.2174/1570159X13666150716165726] [PMID] [PMCID]
53. Yegla B, Parikh V. Developmental suppression of forebrain trkA receptors and attentional capacities in aging rats: A longitudinal study. Behav Brain Res. 2017;335:111-121. [DOI:10.1016/j.bbr.2017.08.017] [PMID] [PMCID]
54. Chen Z-R, Huang J-B, Yang S-L, Hong F-F. Role of Cholinergic Signaling in Alzheimer's Disease. Molecules. 2022;27:1816. [DOI:10.3390/molecules27061816] [PMID] [PMCID]
55. Frinchi M, Scaduto P, Cappello F, Belluardo N, Mudo G. Heat shock protein (Hsp) regulation by muscarinic acetylcholine receptor (mAChR) activation in the rat hippocampus. J Cell Physiol. 2018;233:6107-6116. [DOI:10.1002/jcp.26454] [PMID]
56. Fukunaga K, Yabuki Y. SAK3-Induced Neuroprotection Is Mediated by Nicotinic Acetylcholine Receptors. In: Nicotinic Acetylcholine Receptor Signaling in Neuroprotection. Springer; 2018. pp. 159-171. [DOI:10.1007/978-981-10-8488-1_9] [PMID]
57. Hu Y, Qu ZY, Cao SY, Li Q, Ma L, Krencik R, Xu M, Liu Y. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci Methods. 2016;266:42-49. [DOI:10.1016/j.jneumeth.2016.03.017] [PMID]
58. Martínez-Rubio C, Paulk AC, McDonald EJ, Widge AS, Eskandar EN. Multimodal Encoding of Novelty, Reward, and Learning in the Primate Nucleus Basalis of Meynert. J Neurosci. 2018;38:1942-1958. [DOI:10.1523/JNEUROSCI.2021-17.2017] [PMID] [PMCID]
59. Hampel H, Mesulam MM, Cuello AC, et al. Revisiting the Cholinergic Hypothesis in Alzheimer's Disease: Emerging Evidence from Translational and Clinical Research. J Prev Alzheimers Dis. 2019;6:2-15. [DOI:10.14283/jpad.2018.43] [PMID]
60. Hampel H, Mesulam M, Cuello C, et al. The cholinergic system in the pathophysiology and treatment of Alzheimer's disease. BRAIN. 2018;141:1917-1933. [DOI:10.1093/brain/awy132] [PMID] [PMCID]
61. Majdi A, Sadigh-Eteghad S, RahighAghsan S, Farajdokht F, Vatandoust SM, Namvaran A, Mahmoudi J. Amyloid-β, tau, and the cholinergic system in Alzheimer's disease: Seeking direction in a tangle of clues. Rev Neurosci. 2020;31:391-413. [DOI:10.1515/revneuro-2019-0089] [PMID]
62. Bekris LM, Yu CE, Bird TD, Tsuang DW. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010 Dec;23(4):213-27. PMID: 21045163; PMCID: PMC3044597. [DOI:10.1177/0891988710383571] [PMID] [PMCID]
63. Killin LOJ, Starr JM, Shiue IJ, et al. Environmental risk factors for dementia: a systematic review. BMC Geriatr. 2016;16:175. [DOI:10.1186/s12877-016-0342-y] [PMID] [PMCID]
64. Varshney V, Garabadu D. Ang (1-7)/Mas receptor-axis activation promotes amyloid β-induced altered mitochondrial bioenergetics in discrete brain regions of Alzheimer's disease-like rats. Neuropeptides. 2021;86:102122. [DOI:10.1016/j.npep.2021.102122] [PMID]
65. Cha MY, Han SH, Son SM, et al. Mitochondria-Specific Accumulation of Amyloid β Induces Mitochondrial Dysfunction Leading to Apoptotic Cell Death. PLOS ONE. 2012;7(4):e34929. [DOI:10.1371/journal.pone.0034929] [PMID] [PMCID]
66. Yao M, Nguyen TV, Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci. 2005 Feb 2;25(5):1149-58. [DOI:10.1523/JNEUROSCI.4736-04.2005] [PMID] [PMCID]
67. Wu J, Ishikawa M, Zhang J, Hashimoto K. Brain Imaging of Nicotinic Receptors in Alzheimer's Disease.
68. Teipel SJ, Meindl T, Grinberg L, et al. The Cholinergic System in Mild Cognitive Impairment and Alzheimer's Disease: An in Vivo MRI and DTI Study. Hum Brain Mapp. 2011;32:1349-1362. [DOI:10.1002/hbm.21111] [PMID] [PMCID]
69. Shimohama S, Kawamata J. Roles of Nicotinic Acetylcholine Receptors in the Pathology and Treatment of Alzheimer's and Parkinson's Diseases. In: Akaike A, Shimohama S, Misu Y, eds. Nicotinic Acetylcholine Receptor Signaling in Neuroprotection. Singapore: Springer; 2018. [DOI:10.1007/978-981-10-8488-1_8] [PMID]
70. Mohammadi S, Mahmoudi J, Farajdokht F, et al. Polymorphisms of nicotinic acetylcholine receptors in Alzheimer's disease: a systematic review and data analysis. Egypt J Med Hum Genet. 2022;23:144. [DOI:10.1186/s43042-022-00357-y]
71. Sean Georgi. Nicotinic Acetylcholine Receptors and Alzheimer's Disease Therapeutics: A Review of Current Literature. Journal of Young Investigators. 2005;1539-4026.
72. Guan Z, et al. Loss of Nicotinic Receptors Induced by Beta-Amyloid Peptides in PC12 Cells: Possible Mechanism Involving Lipid Peroxidation. J Neurosci Res. 2003;71:397-406. [DOI:10.1002/jnr.10496] [PMID]
73. Maelicke A, Schrattenholz A, Samochocki M, Radina M, Albuquerque EX. Allosterically potentiating ligands of nicotinic receptors as a treatment strategy for Alzheimer's disease. Behav Brain Res. 2000 Aug;113(1-2):199-206. [DOI:10.1016/S0166-4328(00)00214-X] [PMID]
74. Saeedi M, Rashidy-Pour A. Association between chronic stress and Alzheimer's disease: Therapeutic effects of Saffron. Biomed Pharmacother. 2021;133:110995. [DOI:10.1016/j.biopha.2020.110995] [PMID]
75. Guo Z, Li M, Li X, et al. Crocetin: A Systematic Review. Front Pharmacol. 2022;12:3920. [DOI:10.3389/fphar.2021.745683] [PMID] [PMCID]
76. Yoshino Y, Ishisaka M, Umigai N, Shimazawa M, Tsuruma K, Hara H. Crocetin Prevents Amyloid β Induced Cell Death in Murine Hippocampal Cells. Pharmacol Pharm. 2014;5(1):37. [DOI:10.4236/pp.2014.51007]
77. Wong KH, Xie Y, Huang X, Kadota K, Yao XS, Yu Y, et al. Delivering Crocetin across the Blood-Brain Barrier by Using γ-Cyclodextrin to Treat Alzheimer's Disease. Sci Rep. 2020;10(1):3654. [DOI:10.1038/s41598-020-60293-y] [PMID] [PMCID]
78. Chalatsa I, Arvanitis DA, Koulakiotis NS, Giagini A, Skaltsounis AL, Papadopoulou-Daifoti Z, et al. The Crocus sativus compounds trans-crocin 4 and trans-crocetin modulate the amyloidogenic pathway and tau misprocessing in Alzheimer disease neuronal cell culture models. Front Neurosci. 2019;13:249. [DOI:10.3389/fnins.2019.00249] [PMID] [PMCID]
79. Tiribuzi R, Crispoltoni L, Chiurchiu V, Casella A, Montecchiani C, Del Pino AM, et al. Transcrocetin improves amyloid-β degradation in monocytes from Alzheimer's Disease patients. J Neurol Sci. 2017;372:408−412. [DOI:10.1016/j.jns.2016.11.004] [PMID]
80. Wani A, Al Rihani SB, Sharma A, Weadick B, Govindarajan R, Khan SU, et al. Crocetin Promotes Clearance of Amyloid-β by Inducing Autophagy via the STK11/LKB1-Mediated AMPK Pathway. Autophagy. 2021;17(1):3813. [DOI:10.1080/15548627.2021.1872187] [PMID] [PMCID]
81. Thakur M, Sharma N. Saffron: A golden condiment and repository of nutraceutical potential. Food Sci Res J. 2015;5:59−67.
82. Rashedinia M, Lari P, Abnous K, Hosseinzadeh H. Protective effect of crocin on acrolein-induced tau phosphorylation in the rat brain. Acta Neurobiol Exp. 2015;75(2):208−219. [DOI:10.55782/ane-2015-2029] [PMID]
83. Farideh A, Amir HJ, Fariba K, Asal YL. Reversal effects of crocin on amyloid β-induced memory deficit: Modification of autophagy or apoptosis markers. PharmacolBiochemBehav. 2015;4(1):47−58. [DOI:10.1016/j.pbb.2015.10.011] [PMID]
84. Batarseh YS, Bharate SS, Kumar V, Kumar A, Vishwakarma RA, Bharate SB, et al. Crocus sativus extract tightens the blood-brain barrier, reduces amyloid β load and related toxicity in 5XFAD mice. ACS Chem Neurosci. 2017;8(8):1756−1766. [DOI:10.1021/acschemneuro.7b00101] [PMID] [PMCID]
85. Gammone MA, Riccioni G, D'Orazio N. Marine carotenoids against oxidative stress: effects on human health. Mar Drugs. 2015;13(2015):6226−6246. [DOI:10.3390/md13106226] [PMID] [PMCID]
86. Yang M, Xuan Z, Wang Q, Yan S, Zhou D, Naman CB, et al. Fucoxanthin has potential for therapeutic efficacy in neurodegenerative disorders by acting on multiple targets. NutrNeurosci. 2022;25(10):2167−2180. [DOI:10.1080/1028415X.2021.1926140] [PMID]
87. Jung HA, Ali MY, Choi RJ, Jeong HO, Chung HY, Choi JS. Kinetics and molecular docking studies of fucosterol and fucoxanthin, BACE1 inhibitors from brown algae Undaria pinnatifida and Ecklonia stolonifera. Food Chem Toxicol. 2016;89:104−111. [DOI:10.1016/j.fct.2016.01.014] [PMID]
88. Lin J, Yu J, Zhao J, Zhang K, Zheng J, Wang J, et al. Fucoxanthin, a marine carotenoid, attenuates β-amyloid oligomer-induced neurotoxicity possibly via regulating the PI3K/Akt and the ERK pathways in SH-SY5Y cells. Oxid Med Cell Longev. 2017;2017. [DOI:10.1155/2017/6792543] [PMID] [PMCID]
89. Xiang S, Liu F, Lin J, Chen H, Zhang J. Fucoxanthin Inhibits β-Amyloid Assembly and Attenuates β-Amyloid Oligomer-Induced Cognitive Impairments. J Agric Food Chem. 2017;65(20):4092−4102. [DOI:10.1021/acs.jafc.7b00805] [PMID]
90. Lin J, Huang L, Yu J, Xiang S, Wang J, Zhang J, et al. Fucoxanthin, a marine carotenoid, reverses scopolamine-induced cognitive impairments in mice and inhibits acetylcholinesterase in vitro. Mar Drugs. 2016;14(4):67. [DOI:10.3390/md14040067] [PMID] [PMCID]
91. Gregori M, Masserini M, Mancini S. Nanomedicine for the treatment of Alzheimer's disease. Nanomedicine. 2015;10(7):1203-1218. [DOI:10.2217/nnm.14.206] [PMID]
92. Yang M, Jin L, Wu Z, et al. PLGA-PEG Nanoparticles Facilitate In Vivo Anti-Alzheimer's Effects of Fucoxanthin, a Marine Carotenoid Derived from Edible Brown Algae. J Agric Food Chem. 2021;69(34):9764-9777. [DOI:10.1021/acs.jafc.1c00569] [PMID]
93. Burri BJ, La Frano MR, Zhu C. Absorption, metabolism, and functions of β-cryptoxanthin. Nutr Rev. 2016;74(2):69-82. [DOI:10.1093/nutrit/nuv064] [PMID] [PMCID]
94. Mullan K, Cardwell CR, McGuinness B, et al. Plasma antioxidant status in patients with Alzheimer's disease and cognitively intact elderly: a meta-analysis of case-control studies. J Alzheimers Dis. 2018;62(1):305-317. [DOI:10.3233/JAD-170758] [PMID]
95. Kim J, DellaPenna D. Defining the primary route for lutein synthesis in plants: the role of Arabidopsis carotenoid β-ring hydroxylase CYP97A3. Proc Natl Acad Sci U S A. 2006;103(9):3474-3479. [DOI:10.1073/pnas.0511207103] [PMID] [PMCID]
96. Xu X, Lin X. Advances in the researches of lutein and alzheimer's disease. Chin J Prev Med. 2015;49(5):456.
97. Kiko T, Nakagawa K, Satoh A, et al. Amyloid β Levels in Human Red Blood Cells. PLoS One. 2012;7(11):e49620. [DOI:10.1371/journal.pone.0049620] [PMID] [PMCID]
98. Sajilata MG, Singhal RS, Kamat MY. The Carotenoid Pigment Zeaxanthin-A Review. Compr Rev Food Sci Food Saf. 2008;7:29. [DOI:10.1111/j.1541-4337.2007.00028.x]
99. Abdel-Aal ESM, Akhtar H, Zaheer K, Ali R. Dietary sources of lutein and zeaxanthin carotenoids and their role in eye health. Nutrients. 2013;5(4):1169-1185. [DOI:10.3390/nu5041169] [PMID] [PMCID]
100. Zhang LN, Li MJ, Shang YH, Lao FX. Zeaxanthin Attenuates the Vicious Circle Between Endoplasmic Reticulum Stress and Tau Phosphorylation: Involvement of GSK-3β Activation. J Alzheimers Dis. 2022;86:191. [DOI:10.3233/JAD-215408] [PMID]
101. Nolan JM, Loskutova E, Howard A, et al. The Impact of Supplemental Macular Carotenoids in Alzheimer's Disease: A Randomized Clinical Trial. J Alzheimers Dis. 2015;44(4):1157-1169. [DOI:10.3233/JAD-142265] [PMID]
102. Min JY, Min KB. Serum lycopene, lutein and zeaxanthin, and the risk of Alzheimer's disease mortality in older adults. Dement GeriatrCognDisord. 2014;37(3-4):246-256. [DOI:10.1159/000356486] [PMID]
103. Nolan JM, Loskutova E, Howard AN, et al. Macular Pigment, Visual Function, and Macular Disease among Subjects with Alzheimer's Disease: An Exploratory Study. J Alzheimers Dis. 2014;42(4):1191. [DOI:10.3233/JAD-140507] [PMID] [PMCID]
104. Naghizadeh B, Mansouri M, Ghorbanzadeh B, Farbood Y, Sarkaki A. Protective effects of oral crocin against intracerebroventricular streptozotocin-induced spatial memory deficit and oxidative stress in rats. Phytomedicine. 2013;20(6):537-542. [DOI:10.1016/j.phymed.2012.12.019] [PMID] [PMCID]
105. Greig NH, Lahiri DK, Sambamurti K. Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2002;14(S1):77-91. [DOI:10.1017/S1041610203008676] [PMID]
106. Hira S, Saleem U, Anwar F, Sohail MF, Raza Z, Ahmad B. β-Carotene: a natural compound improves cognitive impairment and oxidative stress in a mouse model of streptozotocin-induced Alzheimer's disease. Biomolecules. 2019 Sep;9(9):441. [DOI:10.3390/biom9090441] [PMID] [PMCID]
107. Li FJ, Shen L, Ji HF. Dietary intakes of vitamin E, vitamin C, and β-carotene and risk of Alzheimer's disease: a meta-analysis. J Alzheimers Dis. 2012;31(2):253-258. [DOI:10.3233/JAD-2012-120349] [PMID]
108. Stuerenburg HJ, Ganzer S. Plasma beta carotene in Alzheimer's disease. Association with cerebrospinal fluid beta-amyloid 1−40, (Abeta40), beta-amyloid 1−42 (Abeta42) and total Tau. Neuro Endocrinol Lett. 2005;26(6):696-698.
109. Boccardi V, Arosio B, Cari L, Bastiani P, Scamosci M, Casati M, Ferri E, Bertagnoli L, Ciccone S, Rossi PD, Nocentini G, Mecocci P. Beta-carotene, telomerase activity and Alzheimer's disease in old age subjects. Eur J Nutr. 2020;59(1):119-126. [DOI:10.1007/s00394-019-01892-y] [PMID]
110. de Oliveira BF, Veloso CA, Nogueira-Machado JA, de Moraes EN, dos Santos RR, Cintra MTG, Chaves MM. Ascorbic acid, alpha-tocopherol, and beta-carotene reduce oxidative stress and proinflammatory cytokines in mononuclear cells of Alzheimer's disease patients. NutrNeurosci. 2012;15(6):244-251. [DOI:10.1179/1476830512Y.0000000019] [PMID]
111. Gervasi T, Pellizzeri V, Benameur Q, Gervasi C, Santini A, Cicero N, Dugo G. Valorization of raw materials from agricultural industry for astaxanthin and β-carotene production by Xanthophyllomycesdendrorhous. Nat Prod Res. 2018;32(13):1554-1561. [DOI:10.1080/14786419.2017.1385024] [PMID]
112. Choi S, Koo S. Efficient syntheses of the keto-carotenoids canthaxanthin, astaxanthin, and astacene. J Org Chem. 2005;70(8):3328-3331. [DOI:10.1021/jo050101l] [PMID]
113. Alessio A, Pergolizzi S, Gervasi T, Aragona M, Lo Cascio P, Cicero N, Lauriano ER. Biological effect of astaxanthin on alcohol-induced gut damage in Carassius auratus used as experimental model. Nat Prod Res. 2021;35:5737. [DOI:10.1080/14786419.2020.1830396] [PMID]
114. Rao AR, Sindhuja H, Dharmesh SM, Sankar KU, Sarada R, Ravishankar GA. Effective inhibition of skin cancer, tyrosinase, and antioxidative properties by astaxanthin and astaxanthin esters from the green alga Haematococcuspluvialis. J Agric Food Chem. 2013;61(16):3842-3851. [DOI:10.1021/jf304609j] [PMID]
115. Fanaee-Danesh E, Gali CC, Tadic J, Zandl-Lang M, Carmen Kober A, Agujetas VR, de Dios C, Tam-Amersdorfer C, Stracke A, Albrecher NM, Manavalan APC, Reiter M, Sun Y, Colell A, Madeo F, Malle E, Panzenboeck U. Astaxanthin exerts protective effects similar to bexarotene in Alzheimer's disease by modulating amyloid-beta and cholesterol homeostasis in blood-brain barrier endothelial cells. BiochimBiophys Acta - Mol Basis Dis. 2019;1865(9):2224-2245. [DOI:10.1016/j.bbadis.2019.04.019] [PMID]
116. Rahman SO, Panda BP, Parvez S, Kaundal M, Hussain S, Akhtar M, Najmi AK. Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Abeta peptides in animal model of Alzheimer's disease. Biomed Pharmacother. 2019;110:47-58. [DOI:10.1016/j.biopha.2018.11.043] [PMID]
117. Zlokovic BV. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008;57(2):178-201. [DOI:10.1016/j.neuron.2008.01.003] [PMID]
118. Rahman SO, Panda BP, Parvez S, Kaundal M, Hussain S, Akhtar M, Najmi AK. Neuroprotective role of astaxanthin in hippocampal insulin resistance induced by Aβ peptides in animal model of Alzheimer's disease. Biomed Pharmacother. 2019;110:47-58. [DOI:10.1016/j.biopha.2018.11.043] [PMID]
119. Cheignon CM, Tomas M, Bonnefont-Rousselot D, Faller P, Hureau C, Collin F. Oxidative stress and the amyloid beta peptide in Alzheimer's disease. Redox Biol. 2018;14:450-464. [DOI:10.1016/j.redox.2017.10.014] [PMID]
120. Che H, Li Q, Zhang T, Wang D, Yang L, Xu J, Yanagita T, Xue C, Chang Y, Wang Y. Effects of astaxanthin and docosahexaenoic-acid-acylated astaxanthin on Alzheimer's disease in APP/PS1 double-transgenic mice. J Agric Food Chem. 2018;66(19):4948-4957. [DOI:10.1021/acs.jafc.8b00988] [PMID]
121. Linnewiel-Hermoni K, Paran E, Wolak T. Carotenoid Supplements and Consumption: Implications for Healthy Aging. Molecular Basis of Nutrition and Aging. 2016; p. 473-489. [DOI:10.1016/B978-0-12-801816-3.00034-0]
122. Wang J, Li L, Wang Z, Cui Y, Tan X, Yuan T, et al. Supplementation of lycopene attenuates lipopolysaccharide-induced amyloidogenesis and cognitive impairments via mediating neuroinflammation and oxidative stress. J NutrBiochem. 2018; 56:16−25. [DOI:10.1016/j.jnutbio.2018.01.009] [PMID]
123. Qu M, Shi H, Wang K, Wang X, Yu N, Guo B. The Associations of Plasma/Serum Carotenoids with Alzheimer's Disease: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2021; 82(3):1055−1066. [DOI:10.3233/JAD-210384] [PMID]
124. Fang Y, Ou S, Wu T, Zhou L, Tang H, Jiang M, et al. Lycopene alleviates oxidative stress via the PI3K/Akt/Nrf2 pathway in a cell model of Alzheimer's disease. PeerJ. 2020; 8:e9308. [DOI:10.7717/peerj.9308] [PMID] [PMCID]
125. Temitope SR. The role of lycopene on the hippocampus of rat model of lipopolysaccharide-induced Alzheimer's disease. Alzheimers Dement. 2021; 17. [DOI:10.1002/alz.058528]
126. Prakash A, Kumar A. Implicating the role of lycopene in restoration of mitochondrial enzymes and BDNF levels in β-amyloid induced Alzheimer' s disease. Eur J Pharmacol. 2014; 741:104−111. [DOI:10.1016/j.ejphar.2014.07.036] [PMID]
127. Hwang S, Lim JW, Kim H. Inhibitory effect of lycopene on amyloid-β-induced apoptosis in neuronal cells. Nutrients. 2017; 9(8):883. [DOI:10.3390/nu9080883] [PMID] [PMCID]
128. Cano A, Turowski P, Ettcheto M, et al. Nanomedicine-based technologies and novel biomarkers for the diagnosis and treatment of Alzheimer's disease: from current to future challenges. J Nanobiotechnol. 2021; 19:122. [DOI:10.1186/s12951-021-00864-x] [PMID] [PMCID]
129. Silva DF, Melo ALP, Uchôa AFC, Pereira GM, Alves AEF, Vasconcellos MC, et al. Biomedical Approach of Nanotechnology and Biological Risks: A Mini-Review. Int J Mol Sci. 2023; 24(23):16719. [DOI:10.3390/ijms242316719] [PMID] [PMCID]
130. Qiu C, Zhang JZ, Wu B, Xu CC, Pang HH, Tu QC, et al. Advanced application of nanotechnology in active constituents of Traditional Chinese Medicines. J Nanobiotechnol. 2023; 21(1):456. [DOI:10.1186/s12951-023-02165-x] [PMID] [PMCID]
131. da Silva LO, Ferreira MRA, Soares LAL. Nanotechnology Formulations Designed with Herbal Extracts and Their Therapeutic Applications - A Review. Chem Biodivers. 2023; 20(8): e202201241. [DOI:10.1002/cbdv.202201241] [PMID]
132. Atanasov AG, Waltenberger B, Pferschy-Wenzig E-M, Linder T, Wawrosch C, Uhrin P, et al. Discovery and resupply of pharmacologically active plant-derived natural products: A review. Biotechnol Adv. 2015; 33(8):1582-1614. [DOI:10.1016/j.biotechadv.2015.08.001] [PMID]
133. Su B, Deng MR, Zhu H. Advances in the discovery and engineering of gene targets for carotenoid biosynthesis in recombinant strains. Biomolecules. 2023; 13(12):1747. [DOI:10.3390/biom13121747] [PMID] [PMCID]
134. Wurtzel ET. Changing form and function through carotenoids and synthetic biology. Plant Physiol. 2019; 179(3):830-843. [DOI:10.1104/pp.18.01122] [PMID] [PMCID]
135. Bjørklund G, Shanaida M, Lysiuk R, Butnariu M, Peana M, Sarac I, et al. Natural compounds and products from an anti-aging perspective. Molecules. 2022; 27:7084. [DOI:10.3390/molecules27207084] [PMID] [PMCID]
136. Babazadeh A, Vahed FM, Liu Q, Siddiqui SA, Kharazmi MS, Jafari SM. Natural bioactive molecules as neuromedicines for the treatment/prevention of neurodegenerative diseases. ACS Omega. 2023;8(4):3667-3683. [DOI:10.1021/acsomega.2c06098] [PMID] [PMCID]
137. Paul D, Kumari PK, Siddiqui N. Yeast Carotenoids: Cost-Effective Fermentation Strategies for Health Care Applications. Fermentation. 2023;9:147. [DOI:10.3390/fermentation9020147]
138. Sirohi P, Verma H, Singh SK, Singh VK, Pandey J, Khusharia S, Kumar D, Kaushalendra, Teotia P, Kumar A. Microalgal Carotenoids: Therapeutic Application and Latest Approaches to Enhance the Production. Curr Issues Mol Biol. 2022;44:6257-6279. [DOI:10.3390/cimb44120427] [PMID] [PMCID]
139. Karavolias NG, Horner W, Abugu MN, Evanega SN. Application of gene editing for climate change in agriculture. Frontiers in Sustainable Food Systems. 2021;5:685801. [DOI:10.3389/fsufs.2021.685801]
140. Mipeshwaree Devi A, Khedashwori Devi K, Premi Devi P, Lakshmipriyari Devi M, Das S. Metabolic engineering of plant secondary metabolites: Prospects and its technological challenges. Frontiers in Plant Science. 2023;14:1171154. [DOI:10.3389/fpls.2023.1171154] [PMID] [PMCID]
141. Molteni C, La Motta C, Valoppi F. Improving the bioaccessibility and bioavailability of carotenoids by means of nanostructured delivery systems: A comprehensive review. Antioxidants. 2022;11:1931. [DOI:10.3390/antiox11101931] [PMID] [PMCID]
142. Terao J. Revisiting carotenoids as dietary antioxidants for human health and disease prevention. Food Funct. 2023;14:7799-7824. [DOI:10.1039/D3FO02330C] [PMID]
143. Naliyadhara N, Kumar A, Gangwar SK, Devanarayanan TN, Hegde M, Alqahtani MS, Abbas M, Sethi G, Kunnumakkara A. Interplay of dietary antioxidants and gut microbiome in human health: What has been learnt thus far? Journal of Functional Foods. 2023;100:105365. [DOI:10.1016/j.jff.2022.105365]
144. Garg M, Sharma N, Sharma S, Kapoor P, Kumar A, Chunduri V, Arora P. Biofortified crops generated by breeding, agronomy, and transgenic approaches are improving lives of millions of people around the world. Frontiers in Nutrition. 2018;5:301899. [DOI:10.3389/fnut.2018.00012] [PMID] [PMCID]
145. Rocha HR, Coelho MC, Gomes AM, Pintado ME. Carotenoids diet: Digestion, gut microbiota modulation, and inflammatory diseases. Nutrients. 2023;15(10):2265. [DOI:10.3390/nu15102265] [PMID] [PMCID]
146. Eroglu A, Al'Abri IS, Kopec RE, Crook N, Bohn T. Carotenoids and their health benefits as derived via their interactions with gut microbiota. Adv Nutr. 2023;14(2):238-255. [DOI:10.1016/j.advnut.2022.10.007] [PMID] [PMCID]
147. Liu L, Huh JR, Shah K. Microbiota and the gut-brain-axis: Implications for new therapeutic design in the CNS. eBioMedicine. 2022;77:103908. [DOI:10.1016/j.ebiom.2022.103908] [PMID] [PMCID]
148. Góralczyk-Bińkowska A, Szmajda-Krygier D, Kozłowska E. The microbiota-gut-brain axis in psychiatric disorders. Int J Mol Sci. 2022;23:11245. [DOI:10.3390/ijms231911245] [PMID] [PMCID]
149. Chasseloup E, Hooker AC, Karlsson MO. Generation and application of avatars in pharmacometric modelling. J PharmacokinetPharmacodyn. 2023;50:411-423. [DOI:10.1007/s10928-023-09873-9] [PMID] [PMCID]
150. Yassine HN, Cordova I, He X, Solomon V, Mack WJ, Harrington MG, et al. Refining omega-3 supplementation trials in APOE4 carriers for dementia prevention. Alzheimers Dement. 2020;16:e039029. [DOI:10.1002/alz.039029]
151. Hendrie HC, Ogunniyi A, Hall KS, Baiyewu O, Unverzagt FW, Gureje O, et al. Incidence of dementia and Alzheimer disease in 2 communities: Yoruba residing in Ibadan, Nigeria, and African Americans residing in Indianapolis, Indiana. JAMA. 2001; 285:739-747. [DOI:10.1001/jama.285.6.739] [PMID]
152. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003; 17:545-580. [DOI:10.1101/gad.1047403] [PMID]
153. Zhao Y, Ji T, Wang H, Li S, Zhao Y, Nie G. Self-assembled peptide nanoparticles as tumor microenvironment activatable probes for tumor targeting and imaging. J Control Release. 2014; 177:11-19. [DOI:10.1016/j.jconrel.2013.12.037] [PMID]
154. Ngowi EE, Wang Y, Qian L, Helmy YA, Anyomi B, Li T, et al. The application of nanotechnology for the diagnosis and treatment of brain diseases and disorders. Front BioengBiotechnol. 2021; 9:629832. [DOI:10.3389/fbioe.2021.629832] [PMID] [PMCID]
155. Cao Y, Zhang R. The application of nanotechnology in treatment of Alzheimer's disease. Front BioengBiotechnol. 2022; 10:1042986. [DOI:10.3389/fbioe.2022.1042986] [PMID] [PMCID]
156. Carneiro P, Morais S, Pereira MC. Nanomaterials towards biosensing of Alzheimer's disease biomarkers. Nanomaterials. 2019; 9(12). [DOI:10.3390/nano9121663] [PMID] [PMCID]
157. Koutsouleris N, Hauser TU, Skvortsova V, De Choudhury M. From promise to practice: towards the realization of AI-informed mental health care in the digital mind: New concepts in mental health 2. Lancet Digit Health. 2022; 4:e829-40. [DOI:10.1016/S2589-7500(22)00153-4] [PMID]
158. Wang F, Zheng J, Cheng J, Zou H, Li M, Deng B, et al. Personalized nutrition: A review of genotype-based nutritional supplementation. Front Nutr. 2022; 9:992986. [DOI:10.3389/fnut.2022.992986] [PMID] [PMCID]
159. Schork NJ, Goetz LH. Single-subject studies in translational nutrition research. Annual Review of Nutrition. 2017; 37:395-422. [DOI:10.1146/annurev-nutr-071816-064717] [PMID] [PMCID]
160. Su W, Xu W, Liu E, Su W, Polyakov NE. Improving the treatment effect of carotenoids on Alzheimer's disease through various nano-delivery systems. Int J Mol Sci. 2023; 24(8):7652. [DOI:10.3390/ijms24087652] [PMID]
161. Patil AD, Kasabe PJ, Dandge PB. Pharmaceutical and nutraceutical potential of natural bioactive pigment: astaxanthin. Nat Prod Bioprospect. 2022; 12:25. [DOI:10.1007/s13659-022-00347-y] [PMID]
162. Si P, Zhu C. Biological and neurological activities of astaxanthin (Review). Mol Med Rep. 2022; 26:300. [DOI:10.3892/mmr.2022.12816] [PMID] [PMCID]
163. Marcello E, Chiono V. Biomaterials-enhanced intranasal delivery of drugs as a direct route for brain targeting. Int J Mol Sci. 2023; 24(4). [DOI:10.3390/ijms24043390] [PMID] [PMCID]
164. Algın-Yapar E. Nasal inserts for drug delivery: An overview. Trop J Pharm Res. 2014; 13(3):459-467. [DOI:10.4314/tjpr.v13i3.22]
165. Cassano R, Servidio C, Trombino S. Biomaterials for drugs nose-brain transport: a new therapeutic approach for neurological diseases. Materials. 2020; 14(7):1802. [DOI:10.3390/ma14071802] [PMID] [PMCID]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
.png)
